Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Board declares interim dividend of Rs 2 per equity share
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The company has reported total income of Rs.826.40 crores for FY 2020-21
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
Subscribe To Our Newsletter & Stay Updated
